Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 930Neoplasms 708Prostatic Neoplasms 490Lung Neoplasms 398Carcinoma, Non-Small-Cell Lung 359Colorectal Neoplasms 357Leukemia, Myeloid, Acute 290Pancreatic Neoplasms 238Brain Neoplasms 227Neoplasm Metastasis 221Multiple Myeloma 214Carcinoma, Hepatocellular 199Head and Neck Neoplasms 182Glioblastoma 181Precursor Cell Lymphoblastic Leukemia-Lymphoma 177Melanoma 173Ovarian Neoplasms 168Squamous Cell Carcinoma of Head and Neck 160Uterine Cervical Neoplasms 144Rectal Neoplasms 144Recurrence 142Hematologic Neoplasms 134Sarcoma 133Triple Negative Breast Neoplasms 127Stomach Neoplasms 127Glioma 126Carcinoma, Renal Cell 123Colonic Neoplasms 113Myelodysplastic Syndromes 112Urinary Bladder Neoplasms 109

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × 90 days × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡